334 related articles for article (PubMed ID: 27409646)
1. Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.
Prizant H; Hammes SR
Endocrinology; 2016 Sep; 157(9):3374-83. PubMed ID: 27409646
[TBL] [Abstract][Full Text] [Related]
2. Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.
Prizant H; Taya M; Lerman I; Light A; Sen A; Mitra S; Foster TH; Hammes SR
Endocr Relat Cancer; 2016 Apr; 23(4):265-80. PubMed ID: 26880751
[TBL] [Abstract][Full Text] [Related]
3. Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.
Prizant H; Sen A; Light A; Cho SN; DeMayo FJ; Lydon JP; Hammes SR
Mol Endocrinol; 2013 Sep; 27(9):1403-14. PubMed ID: 23820898
[TBL] [Abstract][Full Text] [Related]
4. Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.
Krymskaya VP; McCormack FX
Annu Rev Med; 2017 Jan; 68():69-83. PubMed ID: 28099079
[TBL] [Abstract][Full Text] [Related]
5. Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis.
Sun Y; Zhang E; Lao T; Pereira AM; Li C; Xiong L; Morrison T; Haley KJ; Zhou X; Yu JJ
Horm Cancer; 2014 Oct; 5(5):284-98. PubMed ID: 25069840
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
[TBL] [Abstract][Full Text] [Related]
7. Lymphangioleiomyomatosis: Current understanding and potential treatments.
Moir LM
Pharmacol Ther; 2016 Feb; 158():114-24. PubMed ID: 26713679
[TBL] [Abstract][Full Text] [Related]
8. Insulin growth factor binding protein 2 mediates the progression of lymphangioleiomyomatosis.
Li X; Liu X; Zhang L; Li C; Zhang E; Ma W; Fan Q; Yu JJ
Oncotarget; 2017 May; 8(22):36628-36638. PubMed ID: 28410230
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil elastase from myeloid cells promotes TSC2-null tumor growth.
Taya M; Garcia-Hernandez ML; Rangel-Moreno J; Minor B; Gibbons E; Hammes SR
Endocr Relat Cancer; 2020 Apr; 27(4):261-274. PubMed ID: 32045362
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of uterine and adnexal involvement in pulmonary lymphangioleiomyomatosis: a clinicopathologic study of 10 patients.
Hayashi T; Kumasaka T; Mitani K; Terao Y; Watanabe M; Oide T; Nakatani Y; Hebisawa A; Konno R; Takahashi K; Yao T; Seyama K
Am J Surg Pathol; 2011 Dec; 35(12):1776-85. PubMed ID: 22020043
[TBL] [Abstract][Full Text] [Related]
11. In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor.
Gao L; Yue MM; Davis J; Hyjek E; Schuger L
Virchows Arch; 2014 Apr; 464(4):495-503. PubMed ID: 24570392
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.
Grzegorek I; Zuba-Surma E; Chabowski M; Janczak D; Szuba A; Dziegiel P
Anticancer Res; 2015 Jun; 35(6):3341-51. PubMed ID: 26026094
[TBL] [Abstract][Full Text] [Related]
13. Tissue-specific renin-angiotensin system in pulmonary lymphangioleiomyomatosis.
Valencia JC; Pacheco-Rodriguez G; Carmona AK; Xavier J; Bruneval P; Riemenschneider WK; Ikeda Y; Yu ZX; Ferrans VJ; Moss J
Am J Respir Cell Mol Biol; 2006 Jul; 35(1):40-7. PubMed ID: 16474096
[TBL] [Abstract][Full Text] [Related]
14. Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells.
Lu Y; Liu X; Zhang E; Kopras EJ; Smith EP; Astreinidis A; Li C; Leung YK; Ho SM; Yu JJ
PLoS One; 2020; 15(2):e0228894. PubMed ID: 32078667
[TBL] [Abstract][Full Text] [Related]
15. Metastasis of benign tumor cells in tuberous sclerosis complex.
Henske EP
Genes Chromosomes Cancer; 2003 Dec; 38(4):376-81. PubMed ID: 14566858
[TBL] [Abstract][Full Text] [Related]
16. The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models.
Steagall WK; Pacheco-Rodriguez G; Darling TN; Torre O; Harari S; Moss J
Am J Respir Cell Mol Biol; 2018 Jun; 58(6):678-683. PubMed ID: 29406787
[TBL] [Abstract][Full Text] [Related]
17. Lymphangioleiomyomatosis: a metastatic lung disease.
Kundu N; Holz MK
Am J Physiol Cell Physiol; 2023 Feb; 324(2):C320-C326. PubMed ID: 36571446
[TBL] [Abstract][Full Text] [Related]
18. Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM).
Hammes SR; Krymskaya VP
Horm Cancer; 2013 Apr; 4(2):70-7. PubMed ID: 23184699
[TBL] [Abstract][Full Text] [Related]
19. LAM cells biology and lymphangioleiomyomatosis.
Grzegorek I; Drozdz K; Podhorska-Okolow M; Szuba A; Dziegiel P
Folia Histochem Cytobiol; 2013; 51(1):1-10. PubMed ID: 23690211
[TBL] [Abstract][Full Text] [Related]
20. Evolution of lung pathology in lymphangioleiomyomatosis: associations with disease course and treatment response.
Miller S; Stewart ID; Clements D; Soomro I; Babaei-Jadidi R; Johnson SR
J Pathol Clin Res; 2020 Jul; 6(3):215-226. PubMed ID: 32352655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
